99-2014. Announcement of a Pilot Customer Satisfaction Survey: Medical Device Inspection Evaluation  

  • [Federal Register Volume 64, Number 18 (Thursday, January 28, 1999)]
    [Notices]
    [Pages 4426-4431]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-2014]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 99N-0053]
    
    
    Announcement of a Pilot Customer Satisfaction Survey: Medical 
    Device Inspection Evaluation
    
    AGENCY: Food and Drug Administration, HHS.
    
    
    [[Page 4427]]
    
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing a 1-year 
    pilot of a customer satisfaction survey entitled ``Medical Device 
    Inspection Evaluation.'' The purpose of the evaluation is to provide a 
    means whereby the medical device industry can provide feedback in an 
    anonymous way to FDA's Office of Regulatory Affairs (ORA) regarding the 
    medical device inspectional process. ORA intends to utilize a third 
    party to collect the evaluations and trend the data submitted.
    
    DATES: Written comments may be submitted at any time between March 1, 
    1999, through February 28, 2000.
    
    ADDRESSEES: Submit written comments to the Dockets Management Branch 
    (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
    Rockville, MD 20852.
    
    FOR FURTHER INFORMATION CONTACT: Denise D. Dion, Office of Regulatory 
    Affairs, Division of Emergency and Investigational Operations (HFC-
    130), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 
    20857, 301-827-5645, e-mail ddion@ora.fda.gov''.
    
    SUPPLEMENTARY INFORMATION: The Office of Management and Budget (OMB) 
    has granted approval for this evaluation as a customer satisfaction 
    survey. The evaluation is a followup to FDA/ORA's successful medical 
    device industry initiatives, which included preannounced inspections, 
    FDA 483 annotations, and postinspection notification letters. The 
    Medical Device Industry Initiative Grassroots Taskforce, which includes 
    members from industry and industry trade groups from across the nation 
    as well as from FDA/ORA and FDA/Center for Devices and Radiological 
    Health, is responsible for the design and development of this 
    evaluation tool. The University of California-Irvine (UCI) Center for 
    Statistical Consulting, Irvine, CA, is the third party that will 
    collect and collate the evaluation forms and data. The data trends and 
    findings will be made publicly available and will be shared with 
    industry. The evaluation will be piloted for medical device 
    preapproval, quality system/good manufacturing practices, and other 
    related inspections.
        The evaluation forms will contain preprinted information completed 
    by the investigator regarding the name of the firm inspected, date of 
    inspection, whether an FDA 483 was issued, the name of the 
    investigator(s), the applicable FDA District Office and the reason for 
    the inspection. The form will be accompanied by a preaddressed stamped 
    envelope that is to be used to return the form to the UCI Center for 
    Statistical Consulting (UCI). FDA expects the firm official with the 
    most knowledge of the inspection to complete the industry survey 
    portion of the evaluation as soon as possible after the inspection has 
    ended. UCI will report the results by FDA District, FDA Region and 
    nationwide.
        The purpose of including investigator and firm identifiers on the 
    evaluation is to assist UCI in obtaining clarifying information if 
    needed and to determine the number of responses received versus the 
    number of inspections conducted. FDA/ORA intends to share FDA's 
    inspectional accomplishments (numbers) with UCI to help facilitate this 
    determination of response rate. Neither the firm nor investigator 
    identifier information will be entered into the data base or shared 
    with FDA or industry.
        The information collection provisions in this notice have been 
    approved under OMB control number 0910-0360. An agency may not conduct 
    or sponsor, and a person is not required to respond to, a collection of 
    information unless it displays a currently valid OMB control number.
        Interested persons may, at any time between March 1, 1999, through 
    February 28, 2000, submit written comments to the Dockets Management 
    Branch (address above). Two copies of any comments are to be submitted, 
    except that individuals may submit one copy. Comments are to be 
    identified with the docket number found in brackets in the heading of 
    this document. Received comments may be seen in the office above 
    between 9 a.m. and 4 p.m., Monday through Friday.
    
    BILLING CODE 4160-01-F
    
    [[Page 4428]]
    
    [GRAPHIC] [TIFF OMITTED] TN28JA99.007
    
    
    
    [[Page 4429]]
    
    [GRAPHIC] [TIFF OMITTED] TN28JA99.008
    
    
    
    [[Page 4430]]
    
    [GRAPHIC] [TIFF OMITTED] TN28JA99.009
    
    
    
    [[Page 4431]]
    
    [GRAPHIC] [TIFF OMITTED] TN28JA99.010
    
    
    
        Dated: January 21, 1999.
     William K. Hubbard,
     Associate Commissioner for Policy Coordination.
    [FR Doc. 99-2014 Filed 1-27-99; 8:45 am]
    BILLING CODE 4160-01-C
    
    
    

Document Information

Published:
01/28/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-2014
Dates:
Written comments may be submitted at any time between March 1, 1999, through February 28, 2000.
Pages:
4426-4431 (6 pages)
Docket Numbers:
Docket No. 99N-0053
PDF File:
99-2014.pdf